title: Ketek--the FDA perspective.
authors: Janice
authors: J
authors: Soreth
authors: Edward
authors: E
authors: Cox
authors: Sandra
authors: S
authors: Kweder
authors: John
authors: J
authors: Jenkins
authors: Steven
authors: S
authors: Galson
mesh_terms: D026683:Advisory Committees; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D048628:Ketolides / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D015871:Scientific Misconduct; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin